The terms, per the grant. On August 23, 2022, 4D Molecular Therapeutics was issued US11419949B2, covering AAV variant capsids and methods of use. The CPC tags — C07K 14/005 (viral proteins), C12N 15/86 (viral vectors), A61K 48/0016 (gene therapy), plus A61P 27/02 (eye) — describe an engineered delivery vehicle with tissue-targeting properties.
Why the capsid is the franchise: in AAV gene therapy, the therapeutic gene varies by program, but the delivery capsid is the reusable asset that determines which tissues a therapy can reach and how well it evades immunity. An engineered-capsid grant is a platform asset — the kind of IP that gets licensed across many programs and carries a platform royalty.
The structure point: a capsid-platform deal looks more like a tooling license than a single-drug license. The royalty base grows with each program that adopts the capsid, and the value is partly independent of any one therapeutic gene's clinical fate. For a model, that diversification is the premium.
What the grant does not promise: that any program using the capsid succeeds clinically, or that the capsid is free of competing delivery IP. It is an exclusivity claim on an engineered delivery vehicle — a real, reusable asset within a competitive delivery landscape.
The takeaway: when a gene-therapy deal crosses the desk, identify whether the value is in the gene or the delivery vehicle — because capsid platforms carry the broader, compounding royalty. 4D Molecular's August 2022 capsid grant is a dated example of delivery-platform IP.